Prana Biotechnology Limited (PBT)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today » it's FREE! Already a member? Login now!

General Information
Company Name: Prana Biotechnology Limited
Stock Code: PBT
GICS Sub-Industry: Biotechnology
Market Cap ($M): 115
Equiv. Shares (M): 489

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.250 $ 0.240 $ 0.250 $ 0.240 $ 0.235 39,986 $ 0.015  6.383 %

Company Overview

Business Description:
Prana Biotechnology Limited (PBT) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for PBT’s MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer’s, Parkinson’s and Huntington’s diseases and brain cancer.

Strategy Analysis:
The Company's focus is the development of the disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's disease. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration. Prana's lead compound PBT2 has completed Phase IIa clinical trial in patients with early Alzheimer's Disease. Planning is currently underway for a Phase IIb clinical trial of PBT2 in patients with mild to moderate Alzheimer's Disease. Prana is currently validating candidate leads from its MPAC library in the selection of PBT3 and PBT4 series compounds to be designated as follow ups of PBT2 in AD, or for use in secondary alternative indications..

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -3.1 -- 0.0 0.0 0.0 --
2013  A -7.8 -2.3 -- 0.0 0.0 0.0 --
2012  A -5.2 -1.8 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Bionomics (BNO) $227 M -- 6.3247 0.3032 70.7792 9.6631 7.4150 0.00 0.00 0.00
CSL (CSL) $34,619 M 0.0899 0.1809 0.1250 25.5330 21.6208 19.2180 1.64 1.96 2.15
Mesoblast (MSB) $1,512 M -- -- -- -- -- -- 0.00 0.00 0.00
Prana Biotech (PBT) $117 M -- -- -- -- -- -- 0.00 -- --
Sirtex Medical (SRX) $1,265 M 0.2906 0.5102 0.3731 54.2131 35.8987 26.1443 0.00 0.81 1.35

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
PBT -- -- 3.05 -- --
Market 1.20 13.5 1.00 1.03 3.51
Sector 0.74 22.2 3.17 1.34 8.35

Name Position Start Date
Mr Geoffrey Paul Kempler Chairman,Chief Executive Officer 11 November 1997
Mr Brian Derek Meltzer Non-Executive Director 09 December 1999
Dr George William Mihaly Non-Executive Director 09 December 1999
Mr Peter Marks Non-Executive Director 29 July 2005
Mr Lawrence Gozlan Non-Executive Director 08 August 2011
Professor Ira Shoulson Non-Executive Director 13 May 2014

Name Position
Richard Revelins Chief Financial Officer,Company Secretary
Dianne Angus Chief Operating Officer

Calendar of Events
Date Event
28 August 2015 Report (Prelim)
25 February 2015 Report (Interim)
22 October 2014 Report (Annual)
30 September 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Unlisted Property Trusts

A property trust allows you to buy 'units' in an investment operated by a professional investment manager. This Guide will help you understand the risks and decide whether to invest your money.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links